© PR Newswire
22.09.2025
NUTX
LISTED
NASDAQ
NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF WESLEY BAMBURG AS ITS NEW CHIEF OPERATING OFFICER
News Preview
HOUSTON, Sept. 22, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today announced the appoint...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
BAYN
LISTED
XETR
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
News Preview
Bayer announced today progress for two potential therapies against Parkinson’s disease (PD). A first participant received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for PD. At the same time, first European participants have been randomized in REGENERATE-PD, a Phase II...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
OSE
LISTED
EURONEXT
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
News Preview
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
19.09.2025
GNFT
LISTED
EURONEXT
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
19.09.2025
DFTX
LISTED
NASDAQ
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
News Preview
Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellnes...
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
EUZ
LISTED
XETR
Eckert & Ziegler Gains Approval for GalliaPharm® in Japan
News Preview
Berlin, 19 September 2025. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, t......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.09.2025
EUZ
LISTED
XETR
Eckert & Ziegler erhält Zulassung für GalliaPharm® in Japan
News Preview
Berlin, 19. September 2025. Die Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), ein führender Anbieter von Isotopentechnologie für die Nuklearmedizin und radiopharmazeutische Anwendungen, hat von Japans Ministerium für Gesundheit, Arbeit und Soziales (MHLW) die Marktzulassung für den GalliaPharm® 68Ge/68Ga-Radionuklidgenerator erhalte......
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
SKYE
LISTED
NASDAQ
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
News Preview
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
SOBI
LISTED
STO
Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
News Preview
STOCKHOLM, Sept. 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, and Ionis Pharmaceuticals, Inc. today announced that Tryngolza® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the trea...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.09.2025
ORNBV
LISTED
HEL
80,802 Orion Corporation A shares converted into B shares
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 19 SEPTEMBER 2025 at 9.00 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
DBV
LISTED
EURONEXT
DBV Technologies Announces Resignation of Board Member
News Preview
Châtillon, France, September 18, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
News Preview
CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 15, 2025 to 76 new non-executive employees as equity induce...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
18.09.2025
ERF
LISTED
EURONEXT
Eurofins Sustainability Services Introduces Chem-ST™ for Toys: The First Testing Programme to Streamline Global Compliance and Ensure Full Chemical Safety in Toys
News Preview
Eurofins Sustainability Services, a full-service provider for retailers, brands, and manufacturers of consumer products, has grown its extensive service offering to include Chem-ST™ for Toys, an advanced chemical smart testing programme designed to help toy manufacturers, brands, and retailers navigate complex global regulations, reduce recall ris...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
NKTR
LISTED
NASDAQ
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
News Preview
Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis
High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction period
Interim data presented for patients who received placebo during induction period and...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ACB
LISTED
NASDAQ
Aurora Announces Investment into German Manufacturing Facility
News Preview
NASDAQ | TSX: ACB
Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality
EDMONTON, AB, Sept. 18, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years into op...
Themefolio
Profiler
Peergroup
© PR Newswire
18.09.2025
ACB
LISTED
NASDAQ
Aurora Announces Investment into German Manufacturing Facility
News Preview
NASDAQ | TSX: ACB
Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality
EDMONTON, AB, Sept. 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces an investment over five years...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Awarded Grant from the National Institutes of Health
News Preview
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder 5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use dis...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
EAPI
LISTED
EURONEXT
Science Based Targets initiative (SBTi) validates EUROAPI’s near-term climate targets
News Preview
September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels....
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
17.09.2025 / 15:55 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
CHEMM
LISTED
CPH
Notice of Annual General Meeting 2025
News Preview
ANNOUNCEMENT NO. 293...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
News Preview
High responses maintained over four years in nearly half of patients: 48.9% of Week 16 PASI 0 responders sustained complete skin clearance of psoriasis, achieving PASI 0 at every study visit, from Week 16 to four years*Nail psoriasis improvements: 81.8% and 82.7% of patients achieved nail matrix and nail bed mNAPSI 0, respectively, resolution of...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2025
UCB
LISTED
EURONEXT
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
News Preview
Symptom relief sustained to three years: Improvements in the stringent endpoints HiSCR75, HiSCR90, and HiSCR100 at one year were sustained to three years in 81.2%, 64.3%, and 50.1% of patients, respectively*Resolution of inflammatory lesions: Of patients who achieved IHS4-100 (European clinical metric to assess the severity of HS1) at year one, 6...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
XFOR
LISTED
NASDAQ
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
News Preview
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
FYB
LISTED
XETR
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
News Preview
Pressemitteilung // 17. September 2025
Horus Pharma wird Zweitvermarktungspartner für Formycons Eylea®-Biosimilar FYB203 unter der Marke Baiama® in ausgewählten europäischen Ländern
Planegg-Martinsried – Die Formycon AG (FWB: FYB, „Formycon“) gibt bekannt, dass die Klinge Biopharma GmbH („Klinge“), Lizenznehmer und exklusiver Inhaber der weltwe......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.09.2025
FYB
LISTED
XETR
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
News Preview
Press Release // September 17, 2025
Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) announces that Klinge Biopharma GmbH (“Klinge”), the exclusive owner of the global co......
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2025
EHAB
LISTED
NYSE
Enhabit Announces Participation in Jefferies 2025 Healthcare Services Conference
News Preview
Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Jefferies 2025 Healthcare Services Conference.
Enhabit’s President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, Sept. 30 at 10:55 a.m. CT. The fireside chat...
Themefolio
Profiler
Peergroup
© ActuNews
16.09.2025
OXUR
LISTED
EURONEXT
OXURION : Axiodis CRO, de Franse dochtervennootschap van de Oxurion-groep, kondigt een dubbele strategische AI-initiatieven aan om klinische proeven te transformeren
News Preview
• Lancering van digitale tweelingen en virtuele patiënten om klinische studies te versnellen en te beveiligen
• Integratie van AI-modules in Exagis, de eigen eCRF-oplossing van Axiodis
Leuven, BELGIË, 16 september 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) kondigt aan dat zijn dochtervennootschap Axiodis CRO, gespec...
Themefolio
Profiler
Peergroup
© ActuNews
16.09.2025
OXUR
LISTED
EURONEXT
OXURION : Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials
News Preview
• Launch of digital twins and virtual patients to accelerate and enhance clinical trials
• Integration of AI modules into Exagis, Axiodis' proprietary eCRF solution
Leuven, BELGIUM, September 16, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR) announces that its subsidiary, Axiodis CRO, specialized in clinical data manageme...
Themefolio
Profiler
Peergroup
© ActuNews
16.09.2025
OXUR
LISTED
EURONEXT
OXURION : Axiodis CRO, la filiale française du Groupe Oxurion annonce une double initiative stratégique autour de l'IA pour transformer les essais cliniques
News Preview
Lancement de jumeaux numériques et de patients virtuels pour accélérer et fiabiliser les essais cliniques.
Intégration de briques d'IA dans Exagis, solution eCRF propriétaire d'Axiodis.
Leuven, BELGIQUE, 16 septembre 2025, 18h00 - Oxurion NV (Euronext Bruxelles : OXUR), annonce que sa filiale Axiodis CR...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025
News Preview
Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
ORY
LISTED
BME
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
News Preview
In Australia and Europe In Australia and Europe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its clinical study GOAL-HF1. The ongoing study evaluates AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction, with res...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2025
BAYN
LISTED
XETR
10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
News Preview
Bayer today announced a milestone in its Take Care, Now campaign with country superstar and five-time Entertainer of the Year, Luke Bryan, and Feeding America®, the nation’s largest hunger-relief organization. The effort builds on last year’s success to address both food insecurity and “hidden hunger” – nutrient gaps that can impact long-term heal...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
SOON
LISTED
SIX
Eric Bernard takes over as Sonova CEO effective September 15, 2025
News Preview
Sonova Holding AG
/ Key word(s): Personnel
Eric Bernard takes over as Sonova CEO effective September 15, 2025
15.09.2025 / 07:00 CET/CEST
Group Media & Investor Release
Staefa (Switzerland), September 15, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing care solutions, announces that Er......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.09.2025
SOON
LISTED
SIX
Eric Bernard übernimmt als Sonova CEO per 15. September 2025
News Preview
Sonova Holding AG
/ Schlagwort(e): Personalie
Eric Bernard übernimmt als Sonova CEO per 15. September 2025
15.09.2025 / 07:00 CET/CEST
Group Media & Investor Release
Stäfa (Schweiz), 15. September 2025 – Sonova Holding AG (SWX: SOON), ein führender Anbieter innovativer Hörlösungen, gibt bekannt, dass Eric Bernard he......
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2025
OSE
LISTED
EURONEXT
Update on Information Relating to the General Meeting of September 30, 2025
News Preview
Update on Information Relating to the General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.09.2025
CLBX
LISTED
AIMX
Angle PLC Announces Board Changes
News Preview
GUILDFORD, SURREY / ACCESS Newswire / September 12, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, following feedback and discussions with a significant shareholder, Andrew Newland, Chi...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
HELP
LISTED
NASDAQ
CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cybin Inc. (“Cybin” or “the Company”) (NYSE American: CYBN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disc...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
ZEAL
LISTED
CPH
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
News Preview
Company announcement – No. 20 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
CHEMM
LISTED
CPH
Annual Report 2024/25 - Growing revenue and EBITDA
News Preview
ANNOUNCEMENT NO. 292...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
CHEMM
LISTED
CPH
Guidance for the 2025/26 financial year
News Preview
ANNOUNCEMENT NO. 291...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
News Preview
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
ZEAL
LISTED
CPH
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025
News Preview
Press release – No.13 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
TEM
LISTED
NASDAQ
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enh...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
HELP
LISTED
NASDAQ
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Amir Inamdar, Cybin’s Chief Medical Officer, and George Tziras, Cybin’s Chief Busine...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
SN
LISTED
LSE
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant and support its further adoption. Substantial investment into research to expand access and indications have led to these important results designed to...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2025
TFX
LISTED
NYSE
First Patient Enrolled in DUBSTENT DIABETES Trial: Targeting Improved PCI Outcomes for Diabetic Patients
News Preview
The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents The Trial Evaluates a Combined PCI Approach Using Drug-Coated Balloons and Drug-Eluting Stents...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
10.09.2025
AGFB
LISTED
EURONEXT
AGFA HealthCare Strengthens Market Position in KLAS Enterprise Imaging Report 2025
News Preview
CARLSTADT, NJ / ACCESS Newswire / September 10, 2025 / AGFA HealthCare has been recognized by KLAS Research for significant satisfaction gains. Customer satisfaction with AGFA's Enterprise Imaging VNA and XERO® Viewer has increased significantly over the past 18 months, with both solutions named Best in KLAS 2025 winners.KLAS Report - Enterpri...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
IBAB
LISTED
EURONEXT
IBA – TRANSPARENCY NOTIFICATION
News Preview
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
UCB
LISTED
EURONEXT
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
News Preview
Survey insights reveal that despite many participants living with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), feeling misunderstood, a significant majority remain open to dialogue—74% of the 34 Gen Z and 67% of the 216 Millen...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
SOBI
LISTED
STO
Invitation: Sobi's NASP and Uncontrolled Gout call and webcast
News Preview
NASP (previously known as SEL-212) - clinical program overview and uncontrolled gout disease landscape.
STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Investors, analysts, and members of the media are invited to a conference call on Tuesday, 16 September, at 16:30 CEST, 15:30 BST, and 10:30 EDT. The call will present insights from management and Dr. H...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
KPTI
LISTED
NASDAQ
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
News Preview
– Top-Line Results Anticipated in March 2026 –
NEWTON, Mass., Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxol...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
NSIS B
LISTED
CPH
Major shareholder announcement
News Preview
Please read the full announcement in PDF...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
TIL
LISTED
NASDAQ
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
News Preview
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
GMAB
LISTED
CPH
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
GMAB
LISTED
CPH
Capital Increase in Genmab as a Result of Employee Warrant Exercise
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.09.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025
News Preview
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
SECT_B
LISTED
STO
Report from Sectra's 2025 Annual General Meeting
News Preview
LINKÖPING, Sweden, Sept. 9, 2025 /PRNewswire/ -- The Annual General Meeting (AGM) of the international medical imaging IT and cybersecurity company Sectra (STO: SECTB) was held today September 9, 2025. The AGM resolved, in accordance with the Board's proposal, to distribute an ordinary dividend and an extra dividend to the shareholders.
Dividend...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
TEM
LISTED
NASDAQ
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
ACB
LISTED
NASDAQ
Aurora and Copeia Launch English Version of Physician Experience Platform (PEP), Expanding Access to Peer-Reviewed Medical Cannabis Case Studies
News Preview
NASDAQ | TSX: ACB
EDMONTON, AB, Sept. 9, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today announced the launch of the English-language version of the Physician Experience Platform (PEP), in collaboration with German healthcare technology leader, Copeia. Developed as a pe...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
